InspireMD, Inc. (NSPR) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$0.69

From 52W high−64.31%

Volume494584.00

Market cap$35.67M

P/E (TTM)—

P/S (TTM)3.3x

Div yield—

Key dataNov 4, 2026

Open

$0.69

From 52W high

−64.31%

Volume

494584.00

Market cap

$35.67M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.2x

P/E (TTM)

—

RSI (14)

74.8

MomentumView details →

1D Return

+16.63%

YTD Return

−56.33%

SummaryUpdated Jun 1, 2026

InspireMD, Inc. (NASDAQ:NSPR) is an Israeli medical device company founded in 2005 and headquartered in Tel Aviv-Yafo, Israel. The company specializes in developing and commercializing proprietary MicroNet stent platform technology for treating vascular and coronary diseases. InspireMD has been publicly traded since 2011 and operates primarily in international markets including Europe, Latin America, the Middle East, and Asia Pacific through local distributors. The company is currently preparing for its most significant milestone - entering the U.S. market with FDA approval expected for its flagship CGuard Prime system in 2025.

Ask drillr about InspireMD, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.2x

EV/Sales

0.7x

P/S (TTM)

3.3x

P/B (TTM)

1.1x

ProfitabilityView details →

Gross Margin

18.05%

Net Margin

−355.17%

EBITDA Margin

−349.26%

ROE (TTM)

−122.19%

ROA (TTM)

−86.25%

Asset Turnover

0.21x

GrowthView details →

Revenue YoY

+53.42%

EPS YoY

+40.23%

FCF YoY

−35.91%

Revenue CAGR 3Y

+20.19%

EPS CAGR 3Y

+0.00%

EBITDA YoY

+9.12%

MomentumView details →

1D Return

+16.63%

YTD Return

−56.33%

1Y Return

−63.16%

RSI (14)

74.8

vs 50D SMA

+19.69%

vs 200D SMA

−26.39%

Capital & dividendView details →

Debt/Equity

0.06x

Current Ratio

3.80x

Quick Ratio

3.52x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.17

EPS Surprise

15.00%

Beats (12Q)

8/12

Next Q EPS Est

−$0.13

Avg Surprise (4Q)

7.24%

Rev Surprise

28.05%

Financials snapshotView financials →

Revenue (TTM)

10.84M

Net Income (TTM)

−38.50M

Op. CF (TTM)

−41.21M

Next earningsNov 12, 2026 →

Latest newsMore news →

InspireMD announced that it will release its third-quarter 2026 financial results and host a conference call and webcast on November 12, 2026, at 8:30 a.m.6d ago

InspireMD amended certain Series J and Series K warrants, potentially raising up to $11 million in gross proceeds, with the amendments aligning the warrants' trigger event to the anticipated FDA approval of CGuard Prime 80 cm.44d ago

Similar companies

Rapid Micro Biosystems, Inc.RPID TELA Bio, Inc.TELA QT Imaging Holdings, Inc.QTI Davion Healthcare PlcDAVI CVRx, Inc.CVRX Inspira Technologies Oxy B.H.N. Ltd.IINN Find similar companies →

Latest newsMore news →

InspireMD announced that it will release its third-quarter 2026 financial results and host a conference call and webcast on November 12, 2026, at 8:30 a.m.6d ago InspireMD amended certain Series J and Series K warrants, potentially raising up to $11 million in gross proceeds, with the amendments aligning the warrants' trigger event to the anticipated FDA approval of CGuard Prime 80 cm.44d ago